MCID: FML108
MIFTS: 57

Familial Breast Cancer malady

Categories: Rare diseases, Reproductive diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Familial Breast Cancer

Summaries for Familial Breast Cancer

NIH Rare Diseases : 50 familial breast cancer is a cluster of breast cancer within a family. most cases of breast cancer occur sporadically in people with little to no family history of the condition. approximately 5-10% of breast cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to breast cancer that is passed down through a family in an autosomal dominant manner. in some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the brca1, brca2, pten, tp53, cdh1, or stk11 genes (which are each associated with a unique hereditary cancer syndrome). an additional 15-20% of women diagnosed with breast cancer have a significant family history of breast cancer (two or more first-degree or second-degree relatives with breast cancer) but have no identifiable mutation in a gene known to cause a hereditary predisposition to breast cancer. these clusters of breast cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.high-risk cancer screening and other preventative measures such as chemoprevention and/or prophylactic surgeries are typically recommended in women who have an increased risk for breast cancer based on their personal and/or family histories. last updated: 3/23/2015

MalaCards based summary : Familial Breast Cancer, also known as hereditary breast carcinoma, is related to breast cancer and lymphoproliferative syndrome, ebv-associated, autosomal, 1. An important gene associated with Familial Breast Cancer is PALB2 (Partner And Localizer Of BRCA2), and among its related pathways/superpathways are Cell Cycle, Mitotic and DNA Double-Strand Break Repair. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate, and related phenotypes are Decreased homologous recombination repair frequency and cellular

Related Diseases for Familial Breast Cancer

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ
Familial Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Chek2-Related Susceptibility to Breast Cancer
Rad51-Related Susceptibility to Breast Cancer

Diseases related to Familial Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
id Related Disease Score Top Affiliating Genes
1 breast cancer 11.5
2 lymphoproliferative syndrome, ebv-associated, autosomal, 1 10.4 CHEK2 TP53
3 kunjin encephalitis 10.4 BRCA1 BRCA2 ERBB2
4 aorto-ventricular tunnel 10.4 BRCA1 BRCA2
5 breast pericanalicular fibroadenoma 10.4 BRCA1 BRCA2 TP53
6 histiocytic and dendritic cell cancer 10.4 BRCA1 ERBB2 ESR1
7 bacteremia 10.4 BRCA1 BRCA2 PALB2
8 central nervous system mature teratoma 10.4 ERBB2 ESR1 TP53
9 adult central nervous system mature teratoma 10.4 CCND1 ERBB2 TP53
10 male reproductive organ benign neoplasm 10.4 ERBB2 ESR1 TP53
11 mediastinum synovial sarcoma 10.4 BRCA1 BRCA2 TP53
12 lung clear cell-sugar-tumor 10.4 BRCA1 BRCA2 ERBB2 TP53
13 oro-mandibular-limb hypogenesis syndrome 10.4 CCND1 ERBB2 TP53
14 central nervous system primitive neuroectodermal neoplasm 10.4 ERBB2 ESR1 TP53
15 paraphimosis 10.4 BRCA1 BRCA2 ESR1 TP53
16 cellular ependymoma 10.4 BRCA1 BRCA2 TP53
17 intraorbital meningioma 10.4 ATM BRCA1 TP53
18 progesterone resistance 10.4 ATM CHEK2 RAD50
19 childhood brain stem glioma 10.4 ATM CCND1 TP53
20 bladder colloid adenocarcinoma 10.4 BRCA1 BRCA2 ERBB2 TP53
21 arthus reaction 10.4 ERBB2 ESR1 TP53
22 postpartum depression 10.4 BRCA1 ERBB2 ESR1 TP53
23 bladder clear cell adenocarcinoma 10.4 ESR1 TP53
24 immunodeficiency due to a late component of complement deficiency 10.4 BRCA1 BRCA2 ERBB2 TP53
25 skeletal tuberculosis 10.4 CCND1 ERBB2
26 organ system benign neoplasm 10.4 BRCA1 ERBB2 ESR1
27 mycobacterium kansasii 10.4 BRCA1 BRCA2 CCND1 TP53
28 glioma 10.4 ERBB2 ESR1
29 tamoxifen-related endometrial lesion 10.4 ERBB2 RAD51 TP53
30 vulva adenocarcinoma 10.4 ERBB2 ESR1 TP53
31 his bundle tachycardia 10.4 CCND1 ERBB2 ESR1 TP53
32 progesterone-receptor negative breast cancer 10.4 CCND1 ERBB2 ESR1 TP53
33 glanders 10.4 BRCA2 BRIP1 RAD51
34 fallopian tube carcinosarcoma 10.4 BRCA1 BRCA2 ERBB2 ESR1 TP53
35 pyomyositis 10.4 BRCA1 BRCA2 ERBB2 ESR1 TP53
36 metagonimiasis 10.4 BRCA1 BRCA2 ERBB2 ESR1 TP53
37 dental caries 10.4 BRCA1 BRCA2 ERBB2 ESR1 TP53
38 fallopian tube adenocarcinoma 10.4 ERBB2 ESR1 TP53
39 nasal cavity disease 10.4 BRCA1 BRCA2 ERBB2 ESR1 TP53
40 nasopharyngeal carcinoma 10.3 ATM BRCA1 BRCA2 CHEK2 TP53
41 nemaline myopathy 8, autosomal recessive 10.3 BRCA1 BRCA2 BRIP1 ERBB2 PALB2
42 malignant pleural solitary fibrous tumor 10.3 CCND1 ERBB2 ESR1 TP53
43 peroxisome biogenesis disorder 5b 10.3 ATM BRCA1 CHEK2 RAD50 TP53
44 breast malignant phyllodes tumor 10.3 BRCA1 CCND1 ERBB2 ESR1 TP53
45 burn scar 10.3 BRCA1 BRCA2
46 epidermolysis bullosa, nonspecific, autosomal recessive 10.3 ATM BRCA1 CHEK2 RAD50 TP53
47 prostatic adenoma 10.3 ERBB2 ESR1 TP53
48 lethal congenital contracture syndrome 7 10.3 BRCA1 BRCA2
49 bronchogenic cyst 10.3 ATM BRCA1 BRCA2 BRIP1 CHEK2 PALB2
50 bronchiectasis oligospermia 10.3 ATM BRCA1 BRCA2 BRIP1 CHEK2 PALB2

Graphical network of the top 20 diseases related to Familial Breast Cancer:



Diseases related to Familial Breast Cancer

Symptoms & Phenotypes for Familial Breast Cancer

GenomeRNAi Phenotypes related to Familial Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.81 RAD51 BRCA1 BARD1 XRCC2
2 Decreased homologous recombination repair frequency GR00151-A-2 10.81 RAD51 BRCA1 XRCC2
3 Decreased homologous recombination repair frequency GR00236-A-1 10.81 PALB2 RAD51 TSG101 BRCA1 BARD1 BRCA2
4 Decreased homologous recombination repair frequency GR00236-A-2 10.81 PALB2 RAD51 TSG101 BRCA1 BARD1 BRCA2
5 Decreased homologous recombination repair frequency GR00236-A-3 10.81 PALB2 RAD51 BRCA1 BARD1 BRCA2
6 Decreased viability in esophageal squamous lineage GR00235-A 10.1 BRCA1 BRCA2 CCND1 CHEK2 ERBB2 ESR1
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.06 CHEK2 PALB2 PPM1D ATM RAD50 BARD1
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.06 PALB2 PPM1D ATM RAD50 BARD1 RAD51
9 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 10 TP53 TSG101 XRCC2 ATM BARD1 BRCA1
10 Decreased viability with cisplatin GR00101-A-4 9.65 BARD1 BRCA1 BRCA2 BRIP1 RAD51
11 Synthetic lethal with cisplatin GR00101-A-1 9.35 BARD1 BRCA1 BRCA2 BRIP1 RAD51

MGI Mouse Phenotypes related to Familial Breast Cancer:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1
2 growth/size/body region MP:0005378 10.3 TP53 TSG101 XRCC2 ATM BARD1 BRCA1
3 embryo MP:0005380 10.27 ATM BARD1 BRCA1 BRCA2 ERBB2 ESR1
4 endocrine/exocrine gland MP:0005379 10.26 TSG101 ATM BRCA1 BRCA2 BRIP1 CCND1
5 homeostasis/metabolism MP:0005376 10.25 ATM BRCA1 BRCA2 BRIP1 CCND1 CHEK2
6 integument MP:0010771 10.22 PTPRG RAD50 TP53 TSG101 XRCC2 ATM
7 mortality/aging MP:0010768 10.22 ATM BARD1 BRCA1 BRCA2 CCND1 CHEK2
8 neoplasm MP:0002006 10.13 RAD50 TP53 TSG101 XRCC2 ATM BARD1
9 digestive/alimentary MP:0005381 10.05 ERBB2 ESR1 RAD50 TP53 BRCA1 BRCA2
10 limbs/digits/tail MP:0005371 9.97 BRCA1 BRCA2 ERBB2 ESR1 PALB2 RAD50
11 nervous system MP:0003631 9.97 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1
12 reproductive system MP:0005389 9.65 ERBB2 ESR1 PPM1D RAD50 TP53 ATM
13 respiratory system MP:0005388 9.17 BRCA1 CCND1 ERBB2 ESR1 RAD50 TP53

Drugs & Therapeutics for Familial Breast Cancer

Drugs for Familial Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 404)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
2 tannic acid Approved, Nutraceutical Phase 4,Phase 3
3 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
4 Hormones Phase 4,Phase 3,Phase 2,Phase 1
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
6 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
7
Daidzein Phase 4 486-66-8 5281708
8 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
9 Phytoestrogens Phase 4
10 Soy Bean Nutraceutical Phase 4
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
13
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
14
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
15
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
16
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
17
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
18
Zoledronic acid Approved Phase 3 118072-93-8 68740
19
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
20
Cetuximab Approved Phase 3,Phase 2 205923-56-4 56842117 2333
21
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
22
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
23
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
24
Pancrelipase Approved Phase 3,Phase 2 53608-75-6
25
Norepinephrine Approved Phase 3 51-41-2 439260
26
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
27
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
28
Testosterone Approved, Investigational Phase 3,Phase 2 58-22-0 6013
29
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
30
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
31
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
32
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
33
Cytarabine Approved, Investigational Phase 3,Phase 2 147-94-4 6253
34
Methotrexate Approved Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
35
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
36
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
37
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
38
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
39
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
40
Goserelin Approved Phase 3 65807-02-5 47725 5311128
41
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
42
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
43
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
44
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
45
Diphenhydramine Approved Phase 3 58-73-1, 147-24-0 3100
46
Pilocarpine Approved Phase 3 54-71-7, 92-13-7 5910
47
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
48
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
49
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
50
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187

Interventional clinical trials:

(show top 50) (show all 558)
id Name Status NCT ID Phase
1 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
2 Guilford Genomic Medicine Initiative (GGMI) Completed NCT01372553 Phase 4
3 Trial of Patient Navigation-Activation Completed NCT00496678 Phase 4
4 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
5 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed NCT01048606 Phase 4
6 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4
7 Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer Unknown status NCT01452672 Phase 3
8 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3
9 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
10 RCT of a Group Intervention for Women With a Family History of Breast Cancer Completed NCT00150917 Phase 3
11 Fatigue Intervention Trial for Breast Cancer Survivors Completed NCT00513136 Phase 3
12 Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy Completed NCT00612443 Phase 2, Phase 3
13 Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child Completed NCT00194571 Phase 3
14 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3
15 Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer Completed NCT00087178 Phase 3
16 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3
17 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed NCT00041119 Phase 3
18 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
19 Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer Completed NCT00024102 Phase 3
20 Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children Completed NCT00685256 Phase 3
21 Combination Chemotherapy in Treating Women With Breast Cancer Completed NCT00003519 Phase 3
22 Nutrition Intervention in Treating Women With Breast Cancer Completed NCT00002564 Phase 3
23 Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen Completed NCT00016432 Phase 3
24 Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes Completed NCT00003782 Phase 3
25 Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed Completed NCT00002707 Phase 3
26 Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer Completed NCT00320710 Phase 3
27 Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer Completed NCT00002646 Phase 3
28 A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Completed NCT00789581 Phase 3
29 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3
30 The BEACON Study (Breast Cancer Outcomes With NKTR-102) Completed NCT01492101 Phase 3
31 Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer Completed NCT00343382 Phase 3
32 Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Completed NCT01479244 Phase 3
33 Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy Completed NCT00956813 Phase 3
34 S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo Completed NCT00775645 Phase 3
35 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3
36 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
37 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
38 Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Completed NCT00693992 Phase 3
39 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3
40 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00489411 Phase 3
41 Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3
42 Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment Recruiting NCT02525211 Phase 3
43 Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Recruiting NCT01242800 Phase 3
44 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy Recruiting NCT01901094 Phase 3
45 Breast Cancer WEight Loss Study (BWEL Study) Recruiting NCT02750826 Phase 3
46 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3
47 Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy Recruiting NCT02927249 Phase 3
48 Reproductive Health Survivorship Care Plan Recruiting NCT02667626 Phase 3
49 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Recruiting NCT02115282 Phase 3
50 Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy Recruiting NCT02445391 Phase 3

Search NIH Clinical Center for Familial Breast Cancer

Genetic Tests for Familial Breast Cancer

Anatomical Context for Familial Breast Cancer

MalaCards organs/tissues related to Familial Breast Cancer:

39
Breast, Testes, Prostate, Colon, Thyroid

Publications for Familial Breast Cancer

Articles related to Familial Breast Cancer:

(show top 50) (show all 436)
id Title Authors Year
1
Unique Features of Germline Variation in Five Egyptian Familial Breast Cancer Families Revealed by Exome Sequencing. ( 28076423 )
2017
2
Survival in familial and non-familial breast cancer by age and stage at diagnosis. ( 26630529 )
2016
3
RAD51B in Familial Breast Cancer. ( 27149063 )
2016
4
Single nucleotide polymorphisms in the mitochondrial displacement loop and age-at-onset of familial breast cancer. ( 27158866 )
2016
5
Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases. ( 27221885 )
2016
6
Detection of Human Papillomavirus Genotypes and Major BRCA Mutations in Familial Breast Cancer. ( 27186947 )
2016
7
Tumor characteristics and prognosis in familial breast cancer. ( 27899083 )
2016
8
CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients. ( 27983523 )
2016
9
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. ( 26824983 )
2016
10
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. ( 26786923 )
2016
11
Haplotype Analysis of BRCA1 Gene D17S855 and D17S1322 Markers in Iranian Familial Breast Cancer Patients. ( 27510018 )
2016
12
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. ( 28033443 )
2016
13
Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. ( 26969729 )
2016
14
The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. ( 26271414 )
2015
15
Reevaluation of the BRCA2 truncating allele c.9976Aa88>a88T (p.Lys3326Ter) in a familial breast cancer context. ( 26455428 )
2015
16
Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer. ( 26026075 )
2015
17
Phenotypic analysis of familial breast cancer: Comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. ( 25736863 )
2015
18
Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing. ( 26576347 )
2015
19
Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer. ( 25833210 )
2015
20
Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. ( 26283626 )
2015
21
A risk management model for familial breast cancer: A new application using Fuzzy Cognitive Map method. ( 26220142 )
2015
22
Immunoprofile from tissue microarrays to stratify familial breast cancer patients. ( 26312763 )
2015
23
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. ( 26130695 )
2015
24
Epigenetic changes in BRCA1-mutated familial breast cancer. ( 25800897 )
2015
25
Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. ( 25528024 )
2015
26
Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis. ( 26489613 )
2015
27
Familial breast cancer - targeted therapy in secondary and tertiary prevention. ( 25960722 )
2015
28
Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. ( 25713430 )
2015
29
Sister chromatid exchange: A possible approach to characterize familial breast cancer patients. ( 25434423 )
2015
30
Analysis of PTEN in two BRCA1 and BRCA2 wild-type familial breast cancer patients. ( 26600843 )
2015
31
Characterization of familial breast cancer in Saudi Arabia. ( 25923920 )
2015
32
Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. ( 26538066 )
2015
33
Does familial breast cancer and thymoma suggest a cancer syndrome? A family perspective. ( 26344711 )
2015
34
Gene analysis techniques and susceptibility gene discovery inA non-BRCA1/BRCA2 familial breast cancer. ( 25936246 )
2015
35
Considerations for comprehensive assessment of genetic predisposition in familial breast cancer. ( 25472498 )
2015
36
MicroRNA expression profiling in male and female familial breast cancer. ( 25393370 )
2014
37
Analysis of BRCA1and BRCA2 large genomic rearrangements in Sri Lankan familial breast cancer patients and at risk individuals. ( 24906410 )
2014
38
A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. ( 24894343 )
2014
39
Expanding the genetic basis of copy number variation in familial breast cancer. ( 24955146 )
2014
40
PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. ( 24556926 )
2014
41
A Novel Splice Site Mutation in the Non-coding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics. ( 24395671 )
2014
42
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence. ( 25273865 )
2014
43
Altered Significance of D'Amico Risk Classification in Prostate Cancer Patients linked to a Familial Breast Cancer (kConFab) cohort. ( 24784491 )
2014
44
Evaluation of Genetic Variations in miRNA-Binding Sites of BRCA1 and BRCA2 Genes as Risk Factors for the Development of Early-Onset and/or Familial Breast Cancer. ( 25339023 )
2014
45
Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population. ( 24853100 )
2014
46
Mitochondrial DNA variants and risk of familial breast cancer: an exploratory study. ( 24603941 )
2014
47
Identification of sequence polymorphisms in the mitochondrial displacement loop as risk factors for sporadic and familial breast cancer. ( 24430364 )
2014
48
Germline mutations of DICER1 in Chinese women with BRCA1/BRCA2-negative familial breast cancer. ( 25526195 )
2014
49
Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer. ( 25320599 )
2014
50
Large genomic rearrangement of BRCA1 and BRCA2 genes in familial breast cancer patients in Korea. ( 24566764 )
2014

Variations for Familial Breast Cancer

ClinVar genetic disease variations for Familial Breast Cancer:

6 (show top 50) (show all 1957)
id Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.1653T> A (p.Tyr551Ter) single nucleotide variant Pathogenic rs118203997 GRCh37 Chromosome 16, 23646214: 23646214
2 PALB2 NM_024675.3(PALB2): c.3549C> G (p.Tyr1183Ter) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs118203998 GRCh37 Chromosome 16, 23614792: 23614792
3 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
4 CHEK2 NM_007194.3(CHEK2): c.433C> T (p.Arg145Trp) single nucleotide variant Pathogenic/Likely pathogenic rs137853007 GRCh37 Chromosome 22, 29121242: 29121242
5 CHEK2 NM_007194.3(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh37 Chromosome 22, 29091207: 29091207
6 BARD1 NM_000465.3(BARD1): c.1670G> C (p.Cys557Ser) single nucleotide variant risk factor rs28997576 GRCh37 Chromosome 2, 215617178: 215617178
7 TSG101 TSG101, VAL-ALA, 1162T-C single nucleotide variant Pathogenic
8 BRCA2 NM_000059.3(BRCA2): c.5722_5723delCT (p.Leu1908Argfs) deletion Pathogenic rs80359530 GRCh37 Chromosome 13, 32914214: 32914215
9 BRCA2 NM_000059.3(BRCA2): c.2808_2811del4 (p.Ala938Profs) deletion Pathogenic rs80359351 GRCh37 Chromosome 13, 32911300: 32911303
10 BRCA2 NM_000059.3(BRCA2): c.5946delT (p.Ser1982Argfs) deletion Pathogenic rs80359550 GRCh37 Chromosome 13, 32914438: 32914438
11 BRCA2 NM_000059.3(BRCA2): c.771_775delTCAAA (p.Asn257Lysfs) deletion Pathogenic rs80359671 GRCh37 Chromosome 13, 32905145: 32905149
12 BRCA2 NM_000059.3(BRCA2): c.8165C> G (p.Thr2722Arg) single nucleotide variant Pathogenic rs80359062 GRCh37 Chromosome 13, 32937504: 32937504
13 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
14 BRCA2 NM_000059.3(BRCA2): c.8219T> A (p.Leu2740Ter) single nucleotide variant Pathogenic rs80359070 GRCh37 Chromosome 13, 32937558: 32937558
15 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137
16 RAD51 NM_002875.4(RAD51): c.449G> A (p.Arg150Gln) single nucleotide variant Pathogenic rs121917739 GRCh37 Chromosome 15, 41011016: 41011016
17 BRCA1 NM_007294.3(BRCA1): c.181T> G (p.Cys61Gly) single nucleotide variant Pathogenic rs28897672 GRCh37 Chromosome 17, 41258504: 41258504
18 BRCA1 NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs) deletion Pathogenic rs80357783 GRCh37 Chromosome 17, 41276047: 41276048
19 BRCA1 NM_007294.3(BRCA1): c.2296_2297delAG (p.Ser766Terfs) deletion Pathogenic rs80357780 GRCh37 Chromosome 17, 41245251: 41245252
20 BRCA1 NM_007294.3(BRCA1): c.3607C> T (p.Arg1203Ter) single nucleotide variant Pathogenic rs62625308 GRCh37 Chromosome 17, 41243941: 41243941
21 BRCA1 NM_007294.3(BRCA1): c.3748G> T (p.Glu1250Ter) single nucleotide variant Pathogenic rs28897686 GRCh37 Chromosome 17, 41243800: 41243800
22 BRCA1 NM_007294.3(BRCA1): c.3756_3759delGTCT (p.Ser1253Argfs) deletion Pathogenic rs80357868 GRCh37 Chromosome 17, 41243789: 41243792
23 BRCA1 NM_007294.3(BRCA1): c.4065_4068delTCAA (p.Asn1355Lysfs) deletion Pathogenic rs80357508 GRCh37 Chromosome 17, 41243480: 41243483
24 BRCA1 NM_007294.3(BRCA1): c.4327C> T (p.Arg1443Ter) single nucleotide variant Pathogenic rs41293455 GRCh37 Chromosome 17, 41234451: 41234451
25 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
26 BRCA1 NM_007294.3(BRCA1): c.2389G> T (p.Glu797Ter) single nucleotide variant Pathogenic rs62625306 GRCh37 Chromosome 17, 41245159: 41245159
27 BRCA1 NM_007294.3(BRCA1): c.1556delA (p.Lys519Argfs) deletion Pathogenic rs80357662 GRCh37 Chromosome 17, 41245992: 41245992
28 BRCA1 NM_007294.3(BRCA1): c.211A> G (p.Arg71Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80357382 GRCh37 Chromosome 17, 41258474: 41258474
29 BRCA1 NM_007294.3(BRCA1): c.5324T> A (p.Met1775Lys) single nucleotide variant Pathogenic rs41293463 GRCh37 Chromosome 17, 41203088: 41203088
30 BRCA1 NM_007294.3(BRCA1): c.1016delA (p.Lys339Argfs) deletion Pathogenic rs80357618 GRCh37 Chromosome 17, 41246532: 41246532
31 BRCA1 NM_007294.3(BRCA1): c.1018delG (p.Val340Terfs) deletion Pathogenic rs80357774 GRCh37 Chromosome 17, 41246530: 41246530
32 BRCA1 NM_007294.3(BRCA1): c.1121delC (p.Thr374Asnfs) deletion Pathogenic rs80357612 GRCh37 Chromosome 17, 41246427: 41246427
33 BRCA1 NM_007294.3(BRCA1): c.1360_1361delAG (p.Ser454Terfs) deletion Pathogenic rs80357969 GRCh37 Chromosome 17, 41246187: 41246188
34 BRCA1 NM_007294.3(BRCA1): c.1510delC (p.Arg504Valfs) deletion Pathogenic rs80357908 GRCh37 Chromosome 17, 41246038: 41246038
35 BRCA1 NM_007294.3(BRCA1): c.1674delA (p.Gly559Valfs) deletion Pathogenic rs80357600 GRCh37 Chromosome 17, 41245874: 41245874
36 BRCA1 NM_007294.3(BRCA1): c.212+1G> A single nucleotide variant Pathogenic rs80358042 GRCh37 Chromosome 17, 41258472: 41258472
37 BRCA1 NM_007294.3(BRCA1): c.213-11T> G single nucleotide variant Pathogenic rs80358061 GRCh37 Chromosome 17, 41256984: 41256984
38 BRCA1 NM_007294.3(BRCA1): c.2158G> T (p.Glu720Ter) single nucleotide variant Pathogenic rs80356875 GRCh37 Chromosome 17, 41245390: 41245390
39 BRCA1 NM_007294.3(BRCA1): c.2269delG (p.Val757Phefs) deletion Pathogenic rs80357583 GRCh37 Chromosome 17, 41245279: 41245279
40 BRCA1 NM_007294.3(BRCA1): c.2299delA (p.Ser767Alafs) deletion Pathogenic rs80357786 GRCh37 Chromosome 17, 41245249: 41245249
41 BRCA1 NM_007294.3(BRCA1): c.2411_2412delAG (p.Gln804Leufs) deletion Pathogenic rs80357664 GRCh37 Chromosome 17, 41245136: 41245137
42 BRCA1 NM_007294.3(BRCA1): c.2515delC (p.His839Thrfs) deletion Pathogenic rs80357607 GRCh37 Chromosome 17, 41245033: 41245033
43 BRCA1 NM_007294.3(BRCA1): c.2603C> G (p.Ser868Ter) single nucleotide variant Pathogenic rs80356925 GRCh37 Chromosome 17, 41244945: 41244945
44 BRCA1 NM_007294.3(BRCA1): c.2710G> T (p.Glu904Ter) single nucleotide variant Pathogenic rs80357035 GRCh37 Chromosome 17, 41244838: 41244838
45 BRCA1 NM_007294.3(BRCA1): c.302-2A> C single nucleotide variant Pathogenic rs80358011 GRCh37 Chromosome 17, 41256280: 41256280
46 BRCA1 NM_007294.3(BRCA1): c.302-3C> G single nucleotide variant Pathogenic/Likely pathogenic rs80358051 GRCh37 Chromosome 17, 41256281: 41256281
47 BRCA1 NM_007294.3(BRCA1): c.3112G> T (p.Glu1038Ter) single nucleotide variant Pathogenic rs80357161 GRCh37 Chromosome 17, 41244436: 41244436
48 BRCA1 NM_007294.3(BRCA1): c.3228_3229delAG (p.Gly1077Alafs) deletion Pathogenic rs80357635 GRCh37 Chromosome 17, 41244319: 41244320
49 BRCA1 NM_007294.3(BRCA1): c.3358_3359delGT (p.Val1120Terfs) deletion Pathogenic rs80357945 GRCh37 Chromosome 17, 41244189: 41244190
50 BRCA1 NM_007294.3(BRCA1): c.3389C> G (p.Ser1130Ter) single nucleotide variant Pathogenic rs80357405 GRCh37 Chromosome 17, 41244159: 41244159

Expression for Familial Breast Cancer

Search GEO for disease gene expression data for Familial Breast Cancer.

Pathways for Familial Breast Cancer

Pathways related to Familial Breast Cancer according to GeneCards Suite gene sharing:

(show all 47)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1
2
Show member pathways
13.25 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
3
Show member pathways
13.04 ATM BRCA1 BRCA2 CCND1 ERBB2 ESR1
4
Show member pathways
13 ATM BARD1 BRCA1 BRIP1 CHEK2 RAD50
5
Show member pathways
12.95 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
6
Show member pathways
12.68 ATM BARD1 BRCA1 BRIP1 CHEK2 RAD50
7 12.67 BRCA2 CCND1 ERBB2 RAD51 TP53
8
Show member pathways
12.67 ATM BARD1 BRCA1 BRCA2 CCND1 CHEK2
9 12.53 ATM BRCA1 CCND1 ERBB2 TP53
10
Show member pathways
12.51 ATM BRCA1 BRCA2 RAD50 RAD51
11
Show member pathways
12.44 ATM BRCA1 CCND1 CHEK2 PPM1D RAD50
12
Show member pathways
12.42 ATM CHEK2 ERBB2 TP53
13
Show member pathways
12.42 ATM BARD1 BRCA1 CHEK2 RAD50 TP53
14 12.41 ATM CCND1 CHEK2 TP53
15 12.36 ATM BRCA1 BRCA2 BRIP1 CCND1 CHEK2
16 12.35 ATM CCND1 CHEK2 TP53
17
Show member pathways
12.3 ATM BRCA1 CCND1 CHEK2 TP53
18 12.29 CCND1 ERBB2 ESR1 TP53
19
Show member pathways
12.27 ATM BARD1 BRCA1 BRCA2 BRIP1 PALB2
20
Show member pathways
12.22 BRCA1 CCND1 CHEK2 ESR1
21
Show member pathways
12.15 BRCA2 CCND1 ERBB2 RAD51 TP53
22 12.09 ATM CCND1 CHEK2 TP53
23 12.01 ATM CCND1 ERBB2 TP53
24 11.92 BRCA1 BRCA2 BRIP1 PALB2 RAD51
25
Show member pathways
11.91 ATM BRCA1 CHEK2 RAD50 RAD51 TP53
26 11.88 ATM BARD1 BRCA1 BRCA2 CCND1 CHEK2
27 11.82 BARD1 CCND1 TP53
28 11.79 ATM BRCA1 ERBB2 TP53
29
Show member pathways
11.78 ATM BARD1 BRCA1 BRCA2 CHEK2 RAD50
30 11.75 ATM BRCA1 CHEK2 ERBB2 TP53
31 11.74 ATM CCND1 ESR1 RAD50
32 11.73 CCND1 ERBB2 TP53
33
Show member pathways
11.73 ATM CHEK2 TP53
34 11.68 ATM CHEK2 PPM1D TP53
35 11.64 BRCA1 CCND1 ERBB2
36 11.6 ATM BARD1 BRCA1 CHEK2 RAD50 TP53
37 11.56 BRCA1 CCND1 TP53
38 11.56 ATM CHEK2 PPM1D RAD50
39 11.55 ATM BARD1 BRCA1 CCND1 CHEK2 TP53
40 11.54 ATM CCND1 TP53
41
Show member pathways
11.5 ATM BARD1 BRCA1 BRCA2 BRIP1 PALB2
42
Show member pathways
11.49 ATM CHEK2 TP53
43 11.45 BRCA2 CCND1 CHEK2 ESR1
44 11.36 ATM BRCA1 CCND1 TP53
45 11.34 ATM BARD1 BRCA1 RAD50 RAD51 TP53
46 11.09 ATM BRCA1 TP53
47 10.36 CHEK2 TP53

GO Terms for Familial Breast Cancer

Cellular components related to Familial Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.8 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1
2 nuclear chromatin GO:0000790 9.76 ESR1 RAD50 RAD51 TP53
3 PML body GO:0016605 9.65 CHEK2 RAD51 TP53
4 nuclear chromosome, telomeric region GO:0000784 9.62 ATM BRCA2 RAD50 RAD51
5 chromosome, telomeric region GO:0000781 9.61 ATM CHEK2 RAD50
6 nucleus GO:0005634 9.58 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1
7 condensed nuclear chromosome GO:0000794 9.54 BRCA1 RAD50 RAD51
8 BRCA1-A complex GO:0070531 9.4 BARD1 BRCA1
9 lateral element GO:0000800 9.33 BRCA1 BRCA2 RAD51
10 BRCA1-BARD1 complex GO:0031436 9.26 BARD1 BRCA1

Biological processes related to Familial Breast Cancer according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.98 ATM BARD1 KLLN TP53 TSG101
2 cellular response to DNA damage stimulus GO:0006974 9.97 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1
3 regulation of signal transduction by p53 class mediator GO:1901796 9.95 ATM BARD1 BRCA1 BRIP1 CHEK2 RAD50
4 meiotic cell cycle GO:0051321 9.93 RAD50 RAD51 RAD54L XRCC2
5 double-strand break repair GO:0006302 9.93 BRCA1 BRCA2 BRIP1 CHEK2 RAD50 RAD54L
6 double-strand break repair via homologous recombination GO:0000724 9.92 ATM BRCA1 BRCA2 PALB2 RAD50 RAD51
7 double-strand break repair via nonhomologous end joining GO:0006303 9.91 ATM BARD1 BRCA1 RAD50
8 DNA recombination GO:0006310 9.91 BRCA1 BRCA2 PALB2 RAD50 RAD51 RAD54L
9 response to ionizing radiation GO:0010212 9.88 ATM BRCA1 RAD54L XRCC2
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.87 ATM BRCA1 BRCA2 CHEK2
11 multicellular organism growth GO:0035264 9.86 ATM PALB2 XRCC2
12 response to estrogen GO:0043627 9.85 BRCA1 CCND1 ESR1
13 response to gamma radiation GO:0010332 9.85 BRCA2 CHEK2 TP53 XRCC2
14 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.84 ATM CHEK2 TP53
15 reciprocal meiotic recombination GO:0007131 9.84 ATM RAD50 RAD51 XRCC2
16 somitogenesis GO:0001756 9.83 ATM PALB2 XRCC2
17 cellular response to gamma radiation GO:0071480 9.83 ATM CHEK2 RAD51 TP53
18 response to X-ray GO:0010165 9.83 BRCA2 CCND1 RAD51 TP53 XRCC2
19 telomere maintenance via recombination GO:0000722 9.82 BRCA2 RAD50 RAD51
20 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.81 BRCA2 CHEK2 TP53
21 meiotic nuclear division GO:0007126 9.81 RAD51 RAD54L XRCC2
22 DNA double-strand break processing GO:0000729 9.81 ATM BARD1 BRCA1 RAD50
23 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.8 BRCA1 BRCA2 CHEK2 TP53
24 determination of adult lifespan GO:0008340 9.77 ATM RAD54L TP53
25 replicative senescence GO:0090399 9.77 ATM CHEK2 TP53
26 chromosome organization involved in meiotic cell cycle GO:0070192 9.73 ATM RAD50 RAD51
27 mitotic recombination GO:0006312 9.69 RAD51 XRCC2
28 inner cell mass cell proliferation GO:0001833 9.68 BRCA2 PALB2
29 mitotic G1 DNA damage checkpoint GO:0031571 9.68 CCND1 TP53
30 DNA strand renaturation GO:0000733 9.68 RAD54L TP53
31 DNA damage induced protein phosphorylation GO:0006975 9.67 ATM CHEK2
32 protein K6-linked ubiquitination GO:0085020 9.67 BARD1 BRCA1
33 strand invasion GO:0042148 9.66 RAD51 XRCC2
34 negative regulation of telomere capping GO:1904354 9.65 ATM RAD50
35 chordate embryonic development GO:0043009 9.65 BRCA1 BRCA2
36 mitotic recombination-dependent replication fork processing GO:1990426 9.62 BRCA2 RAD51
37 DNA synthesis involved in DNA repair GO:0000731 9.61 ATM BARD1 BRCA1 BRCA2 BRIP1 PALB2
38 strand displacement GO:0000732 9.28 ATM BARD1 BRCA1 BRCA2 BRIP1 PALB2
39 cell cycle GO:0007049 10.18 ATM BRCA1 BRCA2 CCND1 CHEK2 KLLN
40 regulation of apoptotic process GO:0042981 10.02 ATM BRCA1 CHEK2 ESR1 TP53
41 DNA replication GO:0006260 10 ATM BARD1 BRCA1 BRIP1 RAD50
42 DNA repair GO:0006281 10 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2

Molecular functions related to Familial Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.88 CHEK2 ERBB2 ESR1 PTPRG RAD51 TP53
2 ATP binding GO:0005524 9.81 ATM BRIP1 CHEK2 ERBB2 RAD50 RAD51
3 ubiquitin protein ligase binding GO:0031625 9.72 BRCA1 CHEK2 SLC22A18 TP53 TSG101
4 single-stranded DNA binding GO:0003697 9.61 BRCA2 RAD51 XRCC2
5 DNA binding GO:0003677 9.44 ATM BRCA1 BRCA2 BRIP1 ESR1 KLLN
6 nucleotide binding GO:0000166 9.43 ATM BRIP1 CHEK2 ERBB2 RAD50 RAD51
7 recombinase activity GO:0000150 9.37 RAD51 XRCC2
8 protein binding GO:0005515 10.21 ATM BARD1 BRCA1 BRCA2 BRIP1 CCND1

Sources for Familial Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet